Sirt1 More

Perspectives on translational and therapeutic aspects of SIRT1 in inflammaging and senescence. http://t.co/NpCeFcrZCC

— Kelly A. Hogan Ph.D. (@Loose_Lab_Rat) June 17, 2014

PPARδ-mediated inhibition of angiotensin II-induced premature senescence in endothelial cells is SIRT1-dependent. http://t.co/pSRZjvBfEs

— Kelly A. Hogan Ph.D. (@Loose_Lab_Rat) June 17, 2014

Father's Day 2014

------- *EDIT* & Phillies broadcaster Tom McCarthy caught a home run while on air (and threw it back)

Accelerated senescence of cord blood endothelial progenitor cells in premature neonates is driven by SIRT1 decreased expression.

Epidemiological and experimental studies indicate that early vascular dysfunction occurs in low-birth-weight subjects, especially preterm (PT) infants. We recently reported impaired angiogenic activity of endothelial colony-forming cells (ECFCs) in this condition. We hypothesized that ECFC dysfunction in PT might result from premature senescence and investigated the underlying mechanisms. Compared with ECFCs from term neonates (n = 18), ECFCs isolated from PT (n = 29) display an accelerated senescence sustained by growth arrest and increased senescence-associated β-galactosidase activity. Increased p16(INK4a) expression, in the absence of telomere shortening, indicates that premature PT-ECFC aging results from stress-induced senescence. SIRT1 level, a nicotinamide adenine dinucleotide-dependent deacetylase with anti-aging activities, is dramatically decreased in PT-ECFCs and correlated with gestational age. SIRT1 deficiency is subsequent to epigenetic silencing of its promoter. Transient SIRT1 overexpression or chemical induction by resveratrol treatment reverses senescence phenotype, and rescues in vitro PT-ECFC angiogenic defect in a SIRT1-dependent manner. SIRT1 overexpression also restores PT-ECFC capacity for neovessel formation in vivo. We thus demonstrate that decreased expression of SIRT1 drives accelerated senescence of PT-ECFCs, and acts as a critical determinant of the PT-ECFC angiogenic defect. These findings lay new grounds for understanding the increased cardiovascular risk in individuals born prematurely and open perspectives for therapeutic strategy.
http://www.ncbi.nlm.nih.gov/pubmed/24518759

Sirt1: A protein required for integrity of induced pluripotent stem cells

A study published today in the journal Stem Cell Reports, from the Cell Publishing Group, reveals that the SIRT1 protein is needed to lengthen and maintain telomeres during cell reprogramming. SIRT1 also guarantees the integrity of the genome of stem cells that come out of the cell reprogramming process; these cells are known as iPS cells (induced Pluripotent Stem cells). Read more at: http://phys.org/news/2014-04-protein-required-pluripotent-stem-cells.html#jCp
http://phys.org/news/2014-04-protein-required-pluripotent-stem-cells.html#inlRlv

Sirt1: Secret to healthy ageing unlocked!

New York, June 10 (IANS) Ageing is inevitable, but the secret to why some people age more gracefully could lie in the functioning of a protein in our body. Sirtuin1 (SIRT1) protein could be the key to maintain the health of ageing blood stem cells as loss of this protein affects their ability to regenerate blood normally, a study indicates. "Our data shows that SIRT1 is a protein that is required to maintain the health of blood stem cells and supports the possibility that reduced function of this protein with age may compromise healthy ageing," explained Saghi Ghaffari, an associate professor at Icahn School of Medicine at Mount Sinai Hospital in New York City. Humans store stem cell pools in key tissues, including blood. These stem cells can become replacement cells for those lost to wear and tear. But as the blood stem cells age, their ability to regenerate blood declines, potentially contributing to anaemia and the risk of cancers like acute myeloid leukemia and immune deficiency. The new study showed that young blood stem cells that lack SIRT1 behave like old ones. With use of advanced mouse models, the researchers found that blood stem cells without adequate SIRT1 resembled aged and defective stem cells, which are thought to be linked to development of malignancies. "The notion that SIRT1 is a powerful regulator of ageing has been highly debated, but its connection to the health of blood stem cells is now clear," Ghaffari added. "Identifying regulators of stem cell ageing is of major significance for public health because of their potential power to promote healthy ageing and provide targets to combat diseases of ageing," she noted. The findings appeared in the journal Stem Cell Reports.
https://en-maktoob.news.yahoo.com/secret-healthy-ageing-unlocked-094007301.html

Insulin-Metformin Combo Tied to Poorer Survival in Diabetes Study

"The current study suggests that adding a sulfonylurea to metformin should be preferred to adding insulin for most patients who need a second diabetes drug," she said. Sulfonylureas include glibenclamide (Micronase), glimepiride (Amaryl), glipizide (Glucotrol) and others. They work by stimulating the body to make more insulin. Roumie's team found that, compared with those who added a sulfonylurea, those who added insulin to metformin had 30 percent higher odds of heart attack, stroke and death from any cause during the study period. "Although new heart attacks and strokes occurred at similar rates in both groups, mortality was higher in patients who added insulin," she said. Roumie said she doesn't know why the rate of deaths was higher among study patients taking insulin. "We have a number of studies planned to examine possible mechanisms. We are investigating type 2 diabetes outcomes associated with blood sugar swings and with episodes of hypoglycemia (low blood sugar) tied to insulin," she said. Sulfonylureas can also cause low blood sugar levels, according to the American Diabetes Association. The report was published June 11 in the Journal of the American Medical Association.
http://health.usnews.com/health-news/articles/2014/06/10/insulin-metformin-combo-tied-to-poorer-survival-in-diabetes-study

Adoptive T Cell Therapy beats cancer

A medical first at the @NIHClinicalCntr! #Immunotherapy provided long-term remission of #cervical #cancer: http://t.co/qRqUPdHZx0

— NIH - IRP science (@IRPatNIH) June 3, 2014

Omega-3 Polyunsaturated Fatty Acids Antagonize Macrophage Inflammation via Activation of AMPK/SIRT1 Pathway. http://t.co/qSpjlCOm

— Remembrane Srl (@alexchat) October 26, 2012

#AdoptiveTCellTherapy http://t.co/cABh6cCNPP #Immunotherapy #cancer #cervicalcancer #NIH #Macrophage #Tcell #SIRT1 pic.twitter.com/81MkdIW9MD

— FilipinoFood.com (@Webchatroom) June 3, 2014

http://news.yahoo.com/us-therapy-wipes-cervical-cancer-two-women-005449170.html